Skip to main navigation Skip to search Skip to main content

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

  • James J. Vredenburgh
  • , Annick Desjardins
  • , James E. Herndon
  • , Jennifer Marcello
  • , David A. Reardon
  • , Jennifer A. Quinn
  • , Jeremy N. Rich
  • , Sith Sathornsumetee
  • , Sridharan Gururangan
  • , John Sampson
  • , Melissa Wagner
  • , Leighann Bailey
  • , Darell D. Bigner
  • , Allan H. Friedman
  • , Henry S. Friedman
  • Duke University Medical Center

Research output: Contribution to journal › Article › peer-review

1289 Citations (Scopus)

Abstract

Purpose: The prognosis for patients with recurrent glioblastoma multiforme is poor, with a median survival of 3 to 6 months. We performed a phase II trial of bevacizumab, a monoclonal antibody to vascular endothelial growth factor, in combination with irinotecan. Patients and Methods: This phase II trial included two cohorts of patients. The initial cohort, comprising 23 patients, received bevacizumab at 10 mg/kg plus irinotecan every 2 weeks. The dose of irinotecan was based on the patient's anticonvulsant: Patients taking enzyme-inducing antiepileptic drugs (EIAEDs) received 340 mg/m2, and patients not taking EIAEDs received 125 mg/m2. After this regimen was deemed safe and effective, the irinotecan schedule was changed to an accepted brain tumor regimen of four doses in 6 weeks, in anticipation of a phase III randomized trial of irinotecan versus irinotecan and bevacizumab. The second cohort, comprising 12 patients, received bevacizumab 15 mg/kg every 21 days and irinotecan on days 1, 8, 22, and 29. Each cycle was 6 weeks long and concluded with patient evaluations, including magnetic resonance imaging. Results: The 6-month progression-free survival among all 35 patients was 46% (95% CI, 32% to 66%). The 6-month overall survival was 77% (95% CI, 64% to 92%). Twenty of the 35 patients (57%; 95% CI, 39% to 74%) had at least a partial response. One patient developed a CNS hemorrhage, which occurred in his 10th cycle. Four patients developed thromboembolic complications (deep venous thrombosis and/or pulmonary emboli). Conclusion: Bevacizumab and irinotecan is an effective treatment for recurrent glioblastoma multiforme and has moderate toxicity.

Original languageEnglish
Pages (from-to)4722-4729
Number of pages8
JournalJournal of Clinical Oncology
Volume25
Issue number30
DOIs
Publication statusPublished - 20 Oct 2007
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Bevacizumab plus irinotecan in recurrent glioblastoma multiforme'. Together they form a unique fingerprint.

Cite this